Spots Global Cancer Trial Database for bone marrow biopsy

Every month we try and update this database with for bone marrow biopsy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	NCT06210750	T Acute Lymphob... T Lymphoblastic...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging	18 Years - 60 Years	National Cancer Institute (NCI)
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma	NCT05288062	Plasma Cell Mye... Recurrent Plasm... Refractory Plas... Smoldering Plas...	Bone Marrow Bio... Dexamethasone Lenalidomide Pomalidomide	18 Years -	Mayo Clinic
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia	NCT00843882	Anemia Chronic Myelomo... de Novo Myelody... Myelodysplastic...	Bone Marrow Bio... Epoetin Alfa Laboratory Biom... Lenalidomide	18 Years -	National Cancer Institute (NCI)
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	NCT05861050	Blastoid Varian... Mantle Cell Lym... Pleomorphic Var...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax	18 Years - 80 Years	City of Hope Medical Center
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)	NCT00519090	Myelogenous Leu...	Imatinib Nilotinib (AMN1...	18 Years -	Novartis
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	NCT03878095	Malignant Solid... Refractory Chol... Refractory Mali...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	NCT06232044	Recurrent Multi... Refractory Mult...	Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Alliance for Clinical Trials in Oncology
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma	NCT05801913	High Grade B-Ce... Intermediate Gr... Recurrent B-Cel... Refractory B-Ce...	Anti-CD19-CAR C... Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Leukapheresis Lymphodepletion... Magnetic Resona... Multi-peptide C... Positron Emissi... X-Ray Imaging	18 Years -	City of Hope Medical Center
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial	NCT02275533	Acute Myeloid L...	Biospecimen Col... Bone Marrow Bio... Clinical Observ... Echocardiograph... Nivolumab	18 Years -	National Cancer Institute (NCI)
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study	NCT02958462	Myeloid Maligna... Inherited Bone ... Clonal Expansio... Cytopenia Bone Marrow Fai... Clonal Cytopeni... Clonal Hematopo... Hematologic Neo... Hematopoietic a... Hereditary Neop... Idiopathic Cyto... Idiopathic Dysp... Low Risk Myelod...	Biospecimen Col... Bone Marrow Bio... Punch Biopsy Buccal Swab Clinical Evalua... Genetic Counsel... Quality-of-Life... Electronic Heal...	18 Years -	Mayo Clinic
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes	NCT03399773	Acute Biphenoty... Acute Lymphobla... Chronic Myeloge... Hematopoietic a... Myelodysplastic... Myelodysplastic...	Dilanubicel Cyclophosphamid... Fludarabine Thiotepa Total-Body Irra... Umbilical Cord ... Laboratory Biom... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Multigated Acqu... Electrocardiogr... Computed Tomogr...	10 Years - 65 Years	Fred Hutchinson Cancer Center
Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma	NCT06042725	Multiple Myelom...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Chest Radiograp... Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Low Dose Comput... Magnetic Resona... Positron Emissi... Venetoclax X-Ray Imaging Questionnaire A...	18 Years -	Mayo Clinic
MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients	NCT00165386	Prostate Cancer	Magnetic Resona... Bone Marrow Bio...	30 Years -	Dana-Farber Cancer Institute
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial	NCT02275533	Acute Myeloid L...	Biospecimen Col... Bone Marrow Bio... Clinical Observ... Echocardiograph... Nivolumab	18 Years -	National Cancer Institute (NCI)
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation	NCT04203316	Recurrent Acute... Refractory Acut...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy...	24 Months - 21 Years	Children's Oncology Group
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	NCT03878095	Malignant Solid... Refractory Chol... Refractory Mali...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02408861	Advanced Malign... Anal Carcinoma HIV Infection Kaposi Sarcoma Lung Carcinoma Metastatic Mali... Recurrent Class... Refractory Clas... Unresectable So...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Ipilimumab Nivolumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia	NCT04284787	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Azacitidine Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Pembrolizumab Venetoclax	60 Years -	National Cancer Institute (NCI)
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia	NCT02392429	Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Chemotherapy Computed Tomogr... Cytarabine Fluorothymidine... Laboratory Biom... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT05910801	Recurrent Mantl... Refractory Mant...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax	18 Years -	Academic and Community Cancer Research United
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	NCT04764942	Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Mayo Clinic
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells	NCT00353483	Breast Neoplasm...	Peripheral bloo... Breast tissue c... Bone marrow bio...	18 Years -	Washington University School of Medicine
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia	NCT03701282	Chronic Lymphoc... Small Lymphocyt...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Ibrutinib Obinutuzumab Quality-of-Life... Venetoclax	18 Years - 69 Years	National Cancer Institute (NCI)
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT05950113	Recurrent Multi... Refractory Mult...	Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Fludeoxyglucose... Immunotherapy Leukapheresis Magnetic Resona... Positron Emissi...	18 Years - 74 Years	Jonsson Comprehensive Cancer Center
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	NCT03017820	B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab	18 Years -	Mayo Clinic
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma	NCT04840602	Lymphoplasmacyt... Waldenstrom Mac...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Positron Emissi... Rituximab Venetoclax	18 Years -	National Cancer Institute (NCI)
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	NCT04359784	B-Cell Non-Hodg...	Anakinra X-Ray Imaging Positron Emissi... Computed Tomogr... Bone Marrow Asp... Bone Marrow Bio... Lumbar Puncture Biospecimen Col...	18 Years -	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia	NCT02003222	Acute Lymphobla... B Acute Lymphob...	Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging	30 Years - 70 Years	National Cancer Institute (NCI)
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT00557193	Acute Lymphobla... Acute Undiffere... Childhood T Acu...	Asparaginase Biospecimen Col... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Echocardiograph... Etoposide Filgrastim Laboratory Biom... Lestaurtinib Leucovorin Calc... Mercaptopurine Methotrexate Methylprednisol... Multigated Acqu... Pegaspargase Pharmacological... Prednisone Therapeutic Hyd... Vincristine Sul...	- 1 Year	Children's Oncology Group
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome	NCT06287944	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an...	18 Years -	City of Hope Medical Center
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study	NCT02958462	Myeloid Maligna... Inherited Bone ... Clonal Expansio... Cytopenia Bone Marrow Fai... Clonal Cytopeni... Clonal Hematopo... Hematologic Neo... Hematopoietic a... Hereditary Neop... Idiopathic Cyto... Idiopathic Dysp... Low Risk Myelod...	Biospecimen Col... Bone Marrow Bio... Punch Biopsy Buccal Swab Clinical Evalua... Genetic Counsel... Quality-of-Life... Electronic Heal...	18 Years -	Mayo Clinic
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma	NCT05847569	Recurrent Multi... Refractory Mult...	Belantamab Mafo... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Positron Emissi...	18 Years -	Mayo Clinic
Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy	NCT00315796	Cancer	Biophilic Natur...	18 Years -	Johns Hopkins University
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NCT06247540	Recurrent Trans... Refractory Tran... Richter Syndrom... Transformed Chr... Transformed Sma...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Nivolumab Positron Emissi... Rituximab Venetoclax	18 Years -	Northwestern University
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia	NCT04214249	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy	18 Years - 75 Years	National Cancer Institute (NCI)
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia	NCT06311227	Recurrent Hairy... Recurrent Hairy...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Venetoclax	18 Years -	National Cancer Institute (NCI)
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	NCT03418038	Clonal Cytopeni... High Grade B-Ce... Recurrent Diffu... Recurrent Hodgk... Recurrent Lymph... Refractory Diff... Refractory Lymp... Chronic Myelomo...	Ascorbic Acid Carboplatin Cisplatin Cytarabine Dexamethasone Etoposide Gemcitabine Hyd... Ifosfamide Laboratory Biom... Oxaliplatin Placebo Adminis... Questionnaire A... Rituximab Decitabine Biospecimen Col... Core Biopsy Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... Positron Emissi... Magnetic Resona... Central Venous ... Portacath Place... Computed Tomogr...	18 Years -	Mayo Clinic
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	NCT05455697	Diffuse Large B... Grade 3b Follic... High Grade B-Ce...	Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved...	18 Years -	University of Washington
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)	NCT06124157	B Acute Lymphob...	Biospecimen Col... Blinatumomab Bone Marrow Bio... Calaspargase Pe... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Doxorubicin Echocardiograph... Leucovorin Mercaptopurine Methotrexate Multigated Acqu... Pegaspargase Prednisolone Prednisone Radiation Thera... Thioguanine Vincristine	366 Days - 46 Years	National Cancer Institute (NCI)
Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome	NCT05564650	Myelodysplastic... Recurrent Myelo... Refractory Myel...	Navitoclax Venetoclax Decitabine Bone Marrow Bio... Biospecimen Col... Laboratory Biom... Quality-of-Life...	18 Years -	Thomas Jefferson University
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia	NCT02003222	Acute Lymphobla... B Acute Lymphob...	Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging	30 Years - 70 Years	National Cancer Institute (NCI)
Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy	NCT00315796	Cancer	Biophilic Natur...	18 Years -	Johns Hopkins University
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)	NCT00519090	Myelogenous Leu...	Imatinib Nilotinib (AMN1...	18 Years -	Novartis
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	NCT04751383	High Risk Neuro... Recurrent Neuro... Recurrent Osteo... Refractory Neur... Resectable Oste...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab Magnetic Resona... Magrolimab Resection	2 Years - 35 Years	National Cancer Institute (NCI)
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia	NCT02416908	Acute Myeloid L...	Selinexor Cladribine G-CSF Cytarabine Bone marrow bio...	18 Years - 70 Years	Washington University School of Medicine
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer	NCT02849496	Anatomic Stage ... Anatomic Stage ... Locally Advance... Locally Advance... Metastatic Brea... Metastatic HER2... Unresectable Br... Unresectable HE...	Atezolizumab Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bone Scan Computed Tomogr... Magnetic Resona... Olaparib Positron Emissi... Questionnaire A... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome	NCT05873712	Recurrent Trans... Refractory Tran... Transformed Chr... Recurrent Trans... Recurrent Trans... Refractory Tran... Refractory Tran... Refractory Tran...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Fludarabine Leukapheresis Lisocabtagene M... Lymph Node Biop... Positron Emissi... Zanubrutinib	18 Years -	Ohio State University Comprehensive Cancer Center
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	NCT04764942	Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Mayo Clinic
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT06054776	Mantle Cell Lym...	Acalabrutinib Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Echocardiograph... Glofitamab Multigated Acqu... Obinutuzumab Positron Emissi...	18 Years -	City of Hope Medical Center
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	NCT05854966	Acute Myeloid L... Acute Myeloid L... Granulocytic Sa...	CPI 613 Metformin Blood draws Bone marrow bio...	18 Years -	Wake Forest University Health Sciences
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	NCT04375631	Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut...	Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp...	18 Years -	Fred Hutchinson Cancer Center
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma	NCT03321643	Recurrent Diffu... Recurrent Trans... Refractory Diff... Refractory Tran... Richter Syndrom... Transformed Fol...	Atezolizumab Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Gemcitabine Magnetic Resona... Oxaliplatin Positron Emissi... Rituximab	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene	NCT05886049	Acute Myeloid L... Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E...	18 Years - 75 Years	National Cancer Institute (NCI)
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma	NCT04892264	Plasma Cell Mye... Recurrent Plasm... Refractory Plas...	Belantamab Mafo... Daratumumab Dexamethasone Lenalidomide Quality-of-Life... Biospecimen Col... Skeletal Survey... Low Dose Comput... Bone Marrow Asp... Bone Marrow Bio...	18 Years -	Mayo Clinic
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia	NCT02905994	AML	Volasertib Cytarabine Idarubicin Bone Marrow Bio...	18 Years -	Massachusetts General Hospital
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	NCT05861050	Blastoid Varian... Mantle Cell Lym... Pleomorphic Var...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax	18 Years - 80 Years	City of Hope Medical Center
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation	NCT04203316	Recurrent Acute... Refractory Acut...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy...	24 Months - 21 Years	Children's Oncology Group
A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia	NCT00601991	Leukemia	VEGF Trap Bone marrow bio... bone marrow asp... Venipuncture	18 Years -	Vanderbilt-Ingram Cancer Center
MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients	NCT00165386	Prostate Cancer	Magnetic Resona... Bone Marrow Bio...	30 Years -	Dana-Farber Cancer Institute
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma	NCT06169215	Multiple Myelom...	Biospecimen Col... Bone Marrow Bio... Bortezomib Computed Tomogr... Daratumumab Daratumumab and... Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi... Selinexor	-	National Cancer Institute (NCI)
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	NCT03017820	B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab	18 Years -	Mayo Clinic
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01955499	Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Lenalidomide Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma	NCT05886036	Nodular Lymphoc... Recurrent Nodul... Refractory Nodu...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Fludeoxyglucose... Mosunetuzumab Positron Emissi... Rituximab Rituximab and H...	18 Years -	National Cancer Institute (NCI)
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma	NCT06357676	Mantle Cell Lym...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Echocardiograph... FDG-Positron Em... Glofitamab Ibrutinib Magnetic Resona... Obinutuzumab	18 Years -	OHSU Knight Cancer Institute
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)	NCT04385277	Ganglioneurobla... Neuroblastoma	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab FDG-Positron Em... Iobenguane I-12... Irinotecan Isotretinoin Magnetic Resona... Multigated Acqu... Sargramostim Temozolomide	- 30 Years	Children's Oncology Group
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	NCT05981209	Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dexamethasone Echocardiograph... Elotuzumab Magnetic Resona... Mezigdomide X-Ray Imaging	18 Years -	Ohio State University Comprehensive Cancer Center
Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome	NCT05564650	Myelodysplastic... Recurrent Myelo... Refractory Myel...	Navitoclax Venetoclax Decitabine Bone Marrow Bio... Biospecimen Col... Laboratory Biom... Quality-of-Life...	18 Years -	Thomas Jefferson University
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm	NCT05600894	Chronic Myelomo... Myelodysplastic... Myelodysplastic... Myeloproliferat...	Biospecimen Col... Bone Marrow Bio... Decitabine and ... Venetoclax	18 Years -	National Cancer Institute (NCI)
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)	NCT04965597	Bone Marrow Fai... Congenital Ameg... Congenital Pure... Hereditary Side... Paroxysmal Noct... Shwachman-Diamo... Hematologic Neo... Hematologic Neo... Hematologic Neo...	Treosulfan Fludarabine Pho... Tacrolimus Methotrexate Lapine T-Lympho... Peripheral Bloo... Allogeneic Bone... Quality-of-Life... Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	1 Year - 49 Years	Fred Hutchinson Cancer Center
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma	NCT06252675	Mantle Cell Lym...	Obinutuzumab Glofitamab Pirtobrutinib Tumor Imaging Biospecimen Col... ClonoSeq Assay Bone Marrow Bio...	18 Years -	University of California, San Francisco
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers	NCT03134027	Genito Urinary ... Bladder Cancer Kidney Cancer Prostate Cancer	Bone marrow bio... Tumor biopsy	18 Years -	Duke University
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)	NCT06317649	Acute Myeloid L...	Azacitidine Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Gilteritinib Venetoclax	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: